Qualitative insights into promotion of pharmaceutical products in Bangladesh: how ethical are the practices?

BMC Medical Ethics

Syed Masud Ahmed¹  Nahitun Nahar³  Mofijul Islam Shuvro⁴  Sabina Faiz Rashid³  Mahrukh Mohiuddin² 

[1] Centre for Equity and Health Systems, icddr,b and Centre of Excellence for Universal Health Coverage, icddr,b and JPGSPH, icddr,b and JPGSPH, BRAC University, 5th Floor(Level-6), icddrb Building, 68 ShahidTajuddin Ahmed Sharani, Mohakhali, Dhaka 1212, Bangladesh;University Press Limited, Dhaka, Bangladesh;James P Grant School of Public Health (JPGSPH), BRAC University, Dhaka, Bangladesh;Mainstreaming Nutrition in Bangladesh, Dhaka, Bangladesh

关键词: Bangladesh;    Code of Pharmaceutical Marketing Practices;    Pharmaceutical promotional gifts;    Pharmaceutical marketing;    Medical representatives;   

Others  :  1234646
DOI  :  10.1186/s12910-015-0075-z

 received in 2015-07-21, accepted in 2015-11-19,  发布年份 2015

【 摘 要 】

Background

The pharmaceutical market in Bangladesh is highly concentrated (top ten control around 70 % of the market). Due to high competition aggressive marketing strategies are adopted for greater market share, which sometimes cross limit. There is lack of data on this aspect in Bangladesh. This exploratory study aimed to fill this gap by investigating current promotional practices of the pharmaceutical companies including the role of their medical representatives (MR).

Methods

This qualitative study was conducted as part of a larger study to explore the status of governance in health sector in 2009. Data were collected from Dhaka, Chittagong and Bogra districts through in-depth interview (healthcare providers and MRs), observation (physician-MR interaction), and round table discussion (chief executives and top management of the pharmaceutical companies).

Results

Findings reveal a highly structured system geared to generate prescriptions and ensure market share instituted by the pharmaceuticals. A comprehensive training curriculum for the MRs prepares the newly recruited science graduates for generating enough prescriptions by catering to the identified needs and demands of the physicians expressed or otherwise, and thus grab higher market-share for the companies they represent. Approaches such as inducements, persuasion, emotional blackmail, serving family members, etc. are used. The type, quantity and quality of inducements offered to the physicians depend upon his/her capacity to produce prescriptions. The popular physicians are cultivated meticulously by the MRs to establish brand loyalty and fulfill individual and company targets. The physicians, willingly or unwillingly, become part of the system with few exceptions. Neither the regulatory authority nor the professional or consumer rights bodies has any role to control or ractify the process.

Conclusions

The aggressive marketing of the pharmaceutical companies compel their MRs, programmed to maximize market share, to adopt unethical means if and when necessary. When medicines are prescribed and dispensed more for financial interests than for needs of the patients, it reflects system’s failed ability to hold individuals and entities accountable for adhering to basic professional ethics, code of conduct, and statutory laws.

【 授权许可】

   
2015 Mohiuddin et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Ethical criteria for medicinal drug promotion. WHO, Geneva; 1988.
• [2]Lal A. Pharmaceutical drug promotion: how it is being practiced in India? J Assoc Physicians India. 2001; 49:266-73.
• [3]Cardarelli R, Licciardone JC, Taylor LG. A cross-sectional evidence-based review of pharmaceutical promotional marketing brochures and their underlying studies: Is what they tell us important and true? BMC Fam Pract. 2006;7:13. http://www.biomedcentral.com/1471-2296/7/13. Accessed 29 Nov 2015.
• [4]Wazana A. Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA. 2000; 283(3):373-80.
• [5]Laptore JR. Towards a healthy use of pharmaceuticals. Dev Dialogue. 1985; 2:48-55.
• [6]Rohra DK, Gilani AH, Memon IK, Perven G, Khan MT, Zafar H et al.. Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. J Pharm Pharm Sci. 2006; 9(1):50-59.
• [7]Nobhojit R. Who rules the great Indian bazzar. Indian J Med Ethics. 2004; 1:2-3.
• [8]Mandal BK, Yadav SK, Abhishek K, Sah AK. Relationship between doctors and pharmaceutical industry: An ethical perspective. Int J Pharmaceut Biological Arch. 2012; 3(3):415-417.
• [9]Bansal DR, Das RK, DR S. Unethical relationship between doctors and drug companies. Jiafm. 2005; 27(1):40-42.
• [10]Ahmad MNA. Ethical evaluation of pharmaceutical marketing in Pakistan. Acta Bioethica. 2011; 17(2):215-224.
• [11]Ahmed RRDA. Pharmaceutical drug promotion in Pakistan: Issues in ethical and non-ethical practices. Interdisciplinary J Contemporary Res Business. 2012; 4(4):149-164.
• [12]Sur H, Cekin MD. Ethical conduct in health services in Turkey. Turk Stud. 2012; 13(1):85-99.
• [13]Mikhael EM, Alhilali DN. Gift acceptance and its effect on prescribing behavior among Iraqi specialist physicians. Pharm Pharmacol. 2014; 5:705-715.
• [14]Sharma A. Ethical promotional practices by pharmaceutical companies in Nepal: Are they in breach of their promises? Paper submitted for award of MBA degree from Webster University, Thailand Campus 2013. Available from: http://www.webster.ac.th/2012/pdf/thesis/2012-13/mba/Ashim_Sharma.pdf. Accessed 29 Nov 2015.
• [15]Shah SA, Khawaja HA. Unethical marketing practices of pharmaceutical companies in Pakistan: A case study of Sukkur division. Handbook on the Economic, Finance and Management Outlooks. 2013. ISBN:978-969-9347-14-6.
• [16]Hogerzeil HV. The concept of essential medicines: lessons for rich countries. BMJ. 2004; 329(7475):1169-1172.
• [17]Shawon SM. Research report: Pharmaceutical industry of Bangladesh. 2011.
• [18]Begum R. Pharmaceutical industries: potentials and possibilities. NDC J. 2007; 6(1):73-89.
• [19]Drugs, doctors and dinners: How drug companies influence health in developing world (Chapter 3, page 23). Consumers International, London; 2007.
• [20]Bangladesh Health Watch Report 2009: How healthy is health sector governance?. Bangladesh Health Watch Secretariat, Dhaka; 2010.
• [21]Campo K, De S, O Gijsbrechts E et al.. Physicians’ decision process for drug prescription and the impact of pharmaceutical marketing mix instruments. Health Mark Q. 2005; 22(4):73-107.
• [22]Brand R, Kumar P. Detailing gets personal. Pharm Exec. 2003; 23(8):66.
• [23]Creyer EH, Hrsistodoulakis I. Marketing pharmaceutical products to physicians. Mark Health Serv. 1998; 18(2):34-38.
• [24]Goyal R, Pareek P. A review article on prescription behavior of doctors, influenced by the MR in Rajasthan, India. IOSR J Business Management. 2003; 8(1):56-60.
• [25]Patil SB, Meena JS. Work induced stress among MRs in Aurangabad city, Maharashtra. National J Community Med. 2013; 4(2):277-281.
• [26]Roy N, Madhiwalla N, Pai SA. Drug promotional practices in Mumbai: a qualitative study. Indian J Med Ethics. 2007; 4(2):57-61.
• [27]Cutrona SL, Woolhandler S, Lasser KE et al.. Characteristics of recipients of free prescription drug samples: a nationally representative analysis. Am J Public Health. 2008; 98:284-289.
• [28]Groves KE, Sketris I, Tett SE. Prescription drug samples-does this marketing strategy counteract policies for quality use of medicine? Int J Clin Pharmacol Ther. 2003; 28(4):259-271.
• [29]Ahmed RR, Saeed A. Pharmaceutical drug promotion practices in Pakistan: Issues in ethical and non-ethical pharmaceutical practices. Middle-East J Scientific Res. 2014; 20(11):1630-1640.
• [30]Handa M, Vohra A, Srivastava V. Perception of physicians towards pharmaceutical promotion in India. J Medical Marketing. 2013; 13:82-92.